Castration-resistant prostate cancer: Potential targets and therapies

Aijaz Parray; Hifzur R. Siddique; Sanjeev Nanda; Badrinath R. Konety; Mohammad Saleem

doi:10.2147/BTT.S23954

Castration-resistant prostate cancer: Potential targets and therapies

Aijaz Parray, Hifzur R. Siddique, Sanjeev Nanda, Badrinath R. Konety, Mohammad Saleem

General Internal Medicine

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

Original language	English (US)
Pages (from-to)	267-276
Number of pages	10
Journal	Biologics: Targets and Therapy
Volume	6
DOIs	https://doi.org/10.2147/BTT.S23954
State	Published - 2012

Keywords

CRPC
Chemoresistance
Molecular pathways
Neoplastic prostate

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Oncology
Gastroenterology
Pharmacology (medical)

Access to Document

10.2147/BTT.S23954

Cite this

@article{eeef2613099d470aa87b35764613ad97,

title = "Castration-resistant prostate cancer: Potential targets and therapies",

abstract = "The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.",

keywords = "CRPC, Chemoresistance, Molecular pathways, Neoplastic prostate",

author = "Aijaz Parray and Siddique, {Hifzur R.} and Sanjeev Nanda and Konety, {Badrinath R.} and Mohammad Saleem",

year = "2012",

doi = "10.2147/BTT.S23954",

language = "English (US)",

volume = "6",

pages = "267--276",

journal = "Biologics: Targets and Therapy",

issn = "1177-5475",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Castration-resistant prostate cancer

T2 - Potential targets and therapies

AU - Parray, Aijaz

AU - Siddique, Hifzur R.

AU - Nanda, Sanjeev

AU - Konety, Badrinath R.

AU - Saleem, Mohammad

PY - 2012

Y1 - 2012

N2 - The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

AB - The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

KW - CRPC

KW - Chemoresistance

KW - Molecular pathways

KW - Neoplastic prostate

UR - http://www.scopus.com/inward/record.url?scp=84866754770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866754770&partnerID=8YFLogxK

U2 - 10.2147/BTT.S23954

DO - 10.2147/BTT.S23954

M3 - Review article

C2 - 22956858

AN - SCOPUS:84866754770

SN - 1177-5475

VL - 6

SP - 267

EP - 276

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

ER -

Castration-resistant prostate cancer: Potential targets and therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this